Detalhe da pesquisa
1.
Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.
Appl Microbiol Biotechnol
; 107(15): 4777-4787, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37209160
2.
Upstream process optimization and micro- and macrocarrier screening for large-scale production of the oncolytic H-1 protoparvovirus.
Appl Microbiol Biotechnol
; 105(24): 9113-9124, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34782922
3.
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Mol Ther
; 25(12): 2620-2634, 2017 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28967558
4.
A novel scalable, robust downstream process for oncolytic rat parvovirus: isoelectric point-based elimination of empty particles.
Appl Microbiol Biotechnol
; 101(8): 3143-3152, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28091791
5.
Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Clin Cancer Res
; 27(20): 5546-5556, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34426438